Payment overview · 2025
General Payments
$256.44
4 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Joseph Thurick, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MOUNT CARMEL, PA · NPI 1326208109
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Thurick, D.O. received $256.44 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Lokelma by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $109.99 | 42.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.21 | 41.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.62 | 9.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.62 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.44 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $109.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1770 | 115 |
| Gabapentin | Gabapentin | 1107 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 927 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 883 | 54 |
| Furosemide | Furosemide | 882 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 743 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 676 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 666 | 41 |
| Eliquis | Apixaban | 645 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 592 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 529 | 23 |
| Levetiracetam | Levetiracetam | 477 | 15 |
| Potassium Chloride | Potassium Chloride | 473 | 20 |
| Famotidine | Famotidine | 438 | 23 |
| Metformin Hcl | Metformin Hcl | 390 | 23 |
| Donepezil Hcl | Donepezil Hcl | 351 | 12 |
| Lisinopril | Lisinopril | 339 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 338 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 334 | 24 |
| Finasteride | Finasteride | 318 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 287 | suppressed |
| Carvedilol | Carvedilol | 279 | suppressed |
| Meloxicam | Meloxicam | 261 | 22 |
| Buspirone Hcl | Buspirone Hcl | 241 | 12 |
| Trazodone Hcl | Trazodone Hcl | 241 | 19 |
| Risperidone | Risperidone | 234 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 229 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 212 | suppressed |
| Memantine Hcl | Memantine Hcl | 193 | suppressed |
| Aripiprazole | Aripiprazole | 188 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 170 | suppressed |
| Myrbetriq | Mirabegron | 170 | suppressed |
| Olanzapine | Olanzapine | 164 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 161 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 160 | suppressed |
| Losartan Potassium | Losartan Potassium | 159 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 154 | suppressed |
| Allopurinol | Allopurinol | 153 | 12 |
| Lithium Carbonate | Lithium Carbonate | 150 | suppressed |
| Baclofen | Baclofen | 144 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 143 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 137 | suppressed |
| Xarelto | Rivaroxaban | 133 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 132 | suppressed |
| Torsemide | Torsemide | 130 | suppressed |
| Lamotrigine | Lamotrigine | 127 | suppressed |
| Omeprazole | Omeprazole | 126 | 21 |
| Simvastatin | Simvastatin | 122 | 24 |
| Memantine Hcl Er | Memantine Hcl | 120 | suppressed |
| Glipizide | Glipizide | 115 | suppressed |
| Permethrin | Permethrin | 115 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 108 | suppressed |
| Fenofibrate | Fenofibrate | 107 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 105 | suppressed |
| Methocarbamol | Methocarbamol | 101 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 101 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 101 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 91 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 89 | suppressed |
| Ezetimibe | Ezetimibe | 87 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 13 |
| Tradjenta | Linagliptin | 81 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 79 | suppressed |
| Spironolactone | Spironolactone | 79 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 78 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | suppressed |
| Metolazone | Metolazone | 75 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 74 | suppressed |
| Jardiance | Empagliflozin | 73 | suppressed |
| Atenolol | Atenolol | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | suppressed |
| Carbamazepine | Carbamazepine | 68 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | suppressed |
| Mirtazapine | Mirtazapine | 60 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 20 |
| Nifedipine Er | Nifedipine | 59 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 58 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 55 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 55 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Latanoprost | Latanoprost | 54 | suppressed |
| Prednisone | Prednisone | 54 | 13 |
| Primidone | Primidone | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | suppressed |
| Naproxen | Naproxen | 52 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 52 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Zonisamide | Zonisamide | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Paliperidone Er | Paliperidone | 44 | suppressed |
| Calcitriol | Calcitriol | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 11 |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 38 | suppressed |
| Ketoconazole | Ketoconazole | 38 | 17 |
| Lactulose | Lactulose | 38 | suppressed |
| Letrozole | Letrozole | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 19 |
| Valacyclovir | Valacyclovir Hcl | 37 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 33 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 32 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Gemtesa | Vibegron | 30 | suppressed |
| Captopril | Captopril | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Mirabegron Er | Mirabegron | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Xifaxan | Rifaximin | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 17 |
| Atomoxetine Hcl | Atomoxetine Hcl | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Anastrozole | Anastrozole | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Rufinamide | Rufinamide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.44 · 4 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, Cologuard Collection Kit, REXULTI, Tymlos | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error